Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
12.9 EUR | 0.00% | -3.01% | -5.84% |
03:15pm | Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion | MT |
03:14pm | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
Evolution of the average Target Price on Johnson & Johnson
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Johnson & Johnson
Guggenheim | |
Redburn Atlantic | |
Daiwa Securities | |
HSBC | |
DZ Bank | |
Bernstein | |
BofA Securities | |
Morgan Stanley | |
RBC Capital Markets | |
Raymond James | |
Stifel Nicolaus | |
Wells Fargo Securities | |
UBS | |
Atlantic Equities | |
Barclays | |
JPMorgan Chase | |
Credit Suisse | |
SVB Securities LLC | |
Citigroup | |
Goldman Sachs | |
DA Davidson | |
SVB Financial | |
Sanford Bernstein | |
Cantor Fitzgerald | |
J.P. Morgan Chase | |
Cowen | |
SVB Leerink | |
RBC | Brandon Henry |
EPS Revisions
- Stock Market
- Equities
- JNJ Stock
- JNJ0 Stock
- Consensus Johnson & Johnson